Noriko Motoi

<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib

James Bean, Cameron Brennan, Jin‐Yuan Shih et al. · Proceedings of the National Academy of Sciences · 2007 · 1.6K citations

Harbors Met Amplification, Engineering, Pathology +18

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

Akihiko Yoshizawa, Noriko Motoi, Gregory J. Riely et al. · Modern Pathology · 2011 · 987 citations

Further Revision, Surgical Oncology, Proposed Iaslc/ats/ers Classification +9

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

Sizhi Paul Gao, Kevin G. Mark, Kenneth Leslie et al. · Journal of Clinical Investigation · 2007 · 656 citations · Full text

Human Lung Adenocarcinomas, Oncology, Cell Regulation +15

A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee

André L. Moreira, Paolo Ocampo, Yuhe Xia et al. · Journal of Thoracic Oncology · 2020 · 511 citations · Full text

Cancer Detection, Grading System, International Association +11

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset

Kentaro Inamura, Kengo Takeuchi, Yuki Togashi et al. · Modern Pathology · 2009 · 443 citations

Tumor Biology, Young Onset, Medicine +9